Broker Ratings

Insulet Corporation – Consensus ‘buy’ rating and 56.7% Upside Potential

Insulet Corporation which can be found using ticker (PODD) have now 17 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between 360 and 208 calculating the mean target price we have $292.94. Given that the stocks previous close was at $186.97 and the analysts are correct then we can expect a percentage increase in value of 56.7%. Also worth taking note is the 50 day moving average now sits at $248.68 and the 200 day MA is $287.12. The company has a market capitalization of 13.50B. The stock price for the company is currently 193.4 USD

The potential market cap would be $21,156,796,691 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 214.89, revenue per share of 21.06 and a 2.06% return on assets.

Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.

Share on:
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search